When did Stoke Therapeutics, Inc. report Q4 2024 earnings?

Stoke Therapeutics, Inc. (STOK) reported Q4 2024 earnings on March 18, 2025 before market open.

What were Stoke Therapeutics, Inc.'s Q4 2024 revenue and EPS?

Stoke Therapeutics, Inc. reported revenue of $22.6M and diluted EPS of $-0.18 for Q4 2024.

Did Stoke Therapeutics, Inc. beat estimates in Q4 2024?

Revenue beat the consensus estimate of $3.9M by $18.8M. EPS beat the consensus estimate of $-0.51 by $0.33.

Where can I find Stoke Therapeutics, Inc.'s Q4 2024 SEC filings?

You can read the 10-K periodic report (0000950170-25-041170) directly on SEC EDGAR. The filing index links above go to sec.gov.

Stoke Therapeutics, Inc. STOK Q4 2024 Annual earnings

Reported March 18, 2025 · Before market open

Revenue$22.6MBeat by $18.8M Diluted EPS-$0.18Beat by $0.33

Revenue estimate$3.9M

EPS estimate-$0.51

Next report

Aug 11, 2026 (in a month)

Revenue estimate$5.4M

EPS estimate-$0.82

Financials

Q4 2024

Income statement

See full

Revenue$22.6M+707%

Operating income-$13.7M+53.9%

Net income-$10.5M+61.1%

EPS (diluted)-$0.17+71.7%

Balance sheet

See full

Cash & equivalents$128.0M-33.1%

Total debt$4.8M-30.2%

Total equity$229.0M+43.5%

Total assets$271.6M+18.9%

Cash flow

See full

Operating cash flow-$23.2M-12.3%

CapEx$42.0K-81.7%

Free cash flow-$23.2M-11.3%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$584.23M+147%

Enterprise value$461.02M+789%

P/S16×-10.9×

Profitability

See full

Operating margin-277.3%-122pp

Net margin-243.4%-108pp

FCF margin-238.1%-102pp

Returns & leverage

See full

Return on equity-45.8%-9.1pp

Debt / equity0×0.0×

Current ratio5.8×-1.2×

Versus estimates

Revenue

Q1 2026$6.2MMiss by $254.3K Q4 2025$1.4MMiss by $4.4M Q3 2025$10.6MBeat by $6.1M Q2 2025$13.8MBeat by $8.5M Q1 2025$158.6MBeat by $127.1M

Q4 2024$22.6MBeat by $18.8M

Diluted EPS

Q1 2026-$0.79Beat by $0.01 Q4 2025-$0.97Miss by $0.22 Q3 2025-$0.65Miss by $0.11 Q2 2025-$0.40Beat by $0.17 Q1 2025$1.90Beat by $2.27

Q4 2024-$0.18Beat by $0.33

Ask the moment Stoke Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Stoke Therapeutics, Inc. report Q4 2024 earnings?: Stoke Therapeutics, Inc. (STOK) reported Q4 2024 earnings on March 18, 2025 before market open.
What were Stoke Therapeutics, Inc.'s Q4 2024 revenue and EPS?: Stoke Therapeutics, Inc. reported revenue of $22.6M and diluted EPS of $-0.18 for Q4 2024.
Did Stoke Therapeutics, Inc. beat estimates in Q4 2024?: Revenue beat the consensus estimate of $3.9M by $18.8M. EPS beat the consensus estimate of $-0.51 by $0.33.
Where can I find Stoke Therapeutics, Inc.'s Q4 2024 SEC filings?: You can read the 10-K periodic report (0000950170-25-041170) directly on SEC EDGAR. The filing index links above go to sec.gov.